Clotting disorders and preeclampsia;Hémostase et prééclampsie

Annales Francaises d'Anesthesie et de Reanimation

Volumn 29, Issue 5, 2010, Pages

  Ducloy Bouthors, A S ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Abruptio placenta; Clotting diseases and preeclampsia; DIC; IUGR; Thrombocytopenia; Thrombophilia

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRONECTIN; THROMBIN;

ARTICLE; BLOOD CLOTTING DISORDER; CELL ACTIVATION; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ECLAMPSIA; ENDOTHELIUM CELL; ENZYME ACTIVITY; ERYTHROCYTE; FIBRINOLYSIS; HELLP SYNDROME; HUMAN; LEUKOCYTE; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DEPLETION; QUANTITATIVE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; TURNOVER TIME; BLOOD COAGULATION DISORDERS; FEMALE; HEMOSTASIS; PHYSIOLOGY; PRACTICE GUIDELINE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

BLOOD COAGULATION DISORDERS; FEMALE; HEMOSTASIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 77953544581     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2010.03.012     Document Type: Article

References (190)

1. Levy-Toledano S., Dupuy E. Physiologie de l'hémostase primaire. Manuel d'hémostase 1995, 19-36. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
2. Guilin M.C., Bezeaud A. Physiologie de la coagulation plasmatique. Manuel d'hémostase 1995, 37-56. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
3. Alessi M.C., Ailaud M.F., Juhan-Vague I. Physiologie de la fibrinolyse. Manuel d'hémostase 1995, 57-74. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
4. George F., Boutière B., Sampol J. Endothélium et hémostase. Manuel d'hémostase 1995, 75-92. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
5. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004, 114:409-414.
6. O'Riordan M.N., Higgins J.R. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003, 17:385-396.
7. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003, 29:125-130.
8. Kjellberg U., Andersson N.E., Rosén S., Tengborn L., Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999, 81:527-531.
9. Hayashi M., Inoue T., Hoshimoto K., Hirabayashi H., Negishi H., Ohkura T. The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy. Acta Obstet Gynecol Scand 2002, 81:208-213.
10. Paternoster D.M., Stella A., Simioni P., Girolami A., Plebani M. Fibronectin and antithrombin as markers of pre-eclampsia in pregnancy. Eur J Obstet Gynecol Reprod Biol 1996, 70:33-39.
11. Cerneca F., Ricci G., Simeone R., Malisano M., Alberico S., Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997, 73:31-36.
12. Borrelli A.L., De Lucia D., Bernacchi M., Napolitano M., Di Domenico A., Felicetti M., et al. Haemocoagulative modifications correlated with pregnancy. Minerva Ginecol 2006, 58:315-322.
13. Halligan A., Bonnar J., Sheppard B., Darling M. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. BrJ Obstet Gynaecol 1994, 101:488-492.
14. Kruithof E.K., Tran-Thang C., Gudinchet A., Hauert J., Nicoloso G., Genton C., et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987, 69:460-466.
15. Alacacioĝlu I., Ozcan M.A., Alacacioĝlu A., Polat M., Yüksel F., Demirkan F., et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 2004, 114:155-159.
16. Redman C.W.G., Sachs G.P., Sargent I.L. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999, 180:499-506.
17. Bretelle F., Sabatier F., Shojai R., Agostini A., Dignat-George F., Blanc B., et al. Avancées dans la physiopathologie de la pré-éclampsie: place de la réponse inflammatoire. Gynecol Obstet Fertil 2004, 32:482-489.
18. Redman C.W.G., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - A review. Placenta 2003, 24S:S21-S27.
19. Biro E., Hack C.E., van der Post J.A.M., Schaap M.C.L., Sturk A., Nieuwland R. Cell-derived microparticles and complement activation in preeclampsia versus normal pregnancy. Placenta 2007, 28:928-935.
20. Giles C., Inglis T.C.M. Thrombocytopenia and macrothrobocytosis in gestational hypertension. BrJ Obstet Gynaecol 1981, 88:1115-1119.
21. Terao T., Maki M., Ikenoue T., Gotoh K., Murata M., Iwasaki H., et al. The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. Gynecol Obstet Invest 1991, 31:74-85.
22. Kobayashi T., Tokunaga N., Sugimura M., Suzuki K., Kanayama N., Nishiguchi T., et al. Coagulation/fibrinolysis disorder in patients with severe preeclampsia. Semin Thromb Hemost 1999, 25:451-454.
23. Paternoster D.M., Stella A., Mussap M., Plebani M., Gambaro G., Grella P.V. Predictive markers of pre eclampsia in hypertensive disorders of pregnancy. Intern J Gynecol Obstet 1999, 66:237-243.
24. Ballegeer V.C., Spitz B., De Baene L.A., Van Assche A.F., Hidajat M., Criel A.M. Platelet activation and vascular damage in gestational hypertension. Am J Obstet Gynecol 1992, 166:629-633.
25. Saleh A.A., Bottoms S.F., Norman G., Farag A., Mammen E.F. Hemostasis in hypertensive disorders of pregnancy. Obstet Gynecol 1988, 71:719-722.
26. Taylor R.N., Crombleholme W.R., Friedman S.A., Jones L.A., Casal D.C., Roberts J.M. High plasma cellular fibronectin levels correlate with biochemical and clinical features of preeclampsia but cannot be attributed to hypertension alone. Am J Obstet Gynecol 1991, 165:895-901.
27. Thorp J.M., White G.C., Moake J.L., bowes W.A. Von Willebrand factor multimeric levels and patterns in patients with severe preeclampsia. Obstet Gynecol 1990, 75:163-167.
28. Cadroy Y., Grandjean H., Pichon J., Desprats R., Berrebi A., Fournie A., Boneu B. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993, 100:416-420.
29. Caron C., Goudemand J., Marey A., Beague D., Ducroux G., Drouvin F. Are haemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension?. Thrombosis and haemostasis 1991, 66:410-414.
30. Mälikä U.M., Jouppila P., Kirkinen P., Viinikka L., Ylikorkala O. Relation between umbilical prostacyclin production and blood flow in the fetus. Lancet 1983, 323:728-729.
31. Schjetlein R., Abdelnoor M., Haugen G., Husby H., Sandset P.M., Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation. Acta Obstet Gynecol Scand 1999, 78:191-197.
32. Seligman S.P., Buyon J.P., Clancy R.M., Young B.K., Abramson S.B. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994, 171:944-948.
33. Sakai M., Shiozaki A., Sasaki Y., Yoneda S., Saito S. The ratio of interleukin (IL)-18 to IL-12 secreted by peripheral blood mononuclear cells is increased in normal pregnant subjects and decreased in pre-eclamptic patients. J Reprod Immunol 2004, 61:133-143.
34. Ustün Y., Engin-Ustün Y., Mansur Kamaci M. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005, 121:154-158.
35. Yuping W., Yanping Z., Yang G., Philibert L., Lewi D. Maternal serum IL-16 levels were elevated in women with preeclampsia. Am J Obstet Gynecol 2006, 10:426.
36. Hayashi M., Numaguchi M., Watabe H., Yaoi Y. High blood levels of macrophage colony-stimulating factor in preeclampsia. Blood 1996, 88:4426-4428.
37. Hayashi M., Numaguchi M., Ohkubo N., Yaoi Y. Blood macrophage colony-stimulating factor and thrombin-antithrombin III complex concentrations in pregnancy and preeclampsia. Am J Med Sci 1998, 315:251-257.
38. Gervasi M.T., Chaiworapongsa T., Pacora P., Naccasha N., Yoon B.H., Maymon E., et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol 2001, 185:792-797.
39. Andrews W.W., Goldenberg R.L., Faye-Petersen O., Cliver S., Goepfert A.R., Hauth J.C. The Alabama Preterm Birth study: polymorphonuclear and mononuclear cell placental infiltrations, other markers of inflammation, and outcomes in 23- to 32-week preterm newborn infants. Am J Obstet Gynecol 2006, 195:803-808.
40. Stonek F., Hafner E., Metzenbauer M., Katharina S., Stümpflen I., Schneeberger C., et al. Absence of an association of tumor necrosis factor (TNF)-alpha G308A, interleukin-6 (IL-6) G174C and interleukin-10 (IL-10) G1082A polymorphism inwomen with preeclampsia. J Reprod Immunol 2008, 77:85-90.
41. Gotsch F., Romero R., Friel L., Kusanovic J.P., Espinoza J., Erez O., et al. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?. J Matern Fetal Neonatal Med 2007, 20:777-792.
42. McDonagh R.J., Ray J.G., Burrows R., Burrows E.A., Vermeulen M.J. Platelet count may predict abnormal bleeding time among pregnant women with hypertension and preeclampsia. Can J Anesth 2001, 48:563-569.
43. Ramanathan J., Sibai B.M., Vu T., Chauhan D. Correlation between bleeding times and platelet counts in women with preeclampsia undergoing caesarean section. Anesthesiology 1989, 71:188-191.
44. Burrows R.F., Hunter D.J.S., Andrews M., Kelton J.G. A prospective study investigations the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol 1987, 70:334-338.
45. Vincelot A., Nathan N., Collet D., Mehaddi Y., Grandchamp P., Julia A. Platelet function during pregnancy: an evaluation using PFA-100 analyser. Br J Anaesth 2001, 87:890-893.
46. Katz V.L., Thorp J.M., Rosas L., Bowes W.A. The natural history of thrombocytopenia associated with preeclampsia. Am J Obstet Gynecol 1990, 163:1142-1143.
47. Sharma S.K., Philip J., Whitten C.W., Padakandla U.B., Landers D.F. Assesment of changes in coagulation in parturients with preeclampsia using thromboelastography. Anesthesiology 1999, 90:385-390.
48. Rinder H.M., Bonan J.L., Anandan S., Rinder C.S., Rodriges P.A., Smith B.R. Non invasive measurement of platelet kinetics in normal and hypertensive pregnancies. Am J Obstet Gynecol 1994, 170:117-122.
49. Rakoczi I., Tallian F., Bagdany S., Gati I. Platelet life-span in normal pregnancy and preeclampsia as determined by a non-radioisotope technique. Thromb Res 1979, 15:553-556.
50. Perry K.G., Martin J.N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol 1992, 35:338-350.
51. Inglis T.C.M., Stuart J., George A.J., Davies A.J. Haemostatic and rheological changes in normal pregnancy and preeclampsia. Br J Haematol 1982, 50:461-465.
52. Samuels P., Main E.K., Tomaski A., Mennuti M.T., Gabbe S.G., Cines D.B. Abnormalities in platelet antiglobulin tets in preeclamptic mothers and their neonates. Am J Obstet Gynecol 1987, 157:109-113.
53. Konijnenberg A., Stokkers E.W., Van Der Post J.A.M., Schaap M.C.L., Boer K., Bleker O.P., et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997, 176:461-469.
54. Karalis I., Nadar S.K., Al Yemeni E., Blann A.D., Lip G.H.Y. Platelet activation in pregnancy-induced hypertension. Thrombosis Research 2005, 116:377-383.
55. Holthe M.R., Lyberg T., Staff A.C., Berge L.N. Leukocyte-platelet interaction in pregnancies complicated with preeclampsia. Platelets 2005, 16:91-97.
56. Norris L.A., Sheppard B.L., Burke G., Bonnar J. Platelet activation in normotensive and hypertensive pregnancies complicated by intrauterine growth retardation. Br J Obstet Gynaecol 1994, 101:209-214.
57. Zemel M.B., Zemel P.C., Berry S., Norman G., Kowalczyk C., Sokol R.J., et al. Altered platelet calcium metabolism as an early predictor of increased peripheral vascular resistance and preeclampsia in urban black women. N Engl J Med 1990, 323:434-438.
58. Kelton J.G., Hunter D.J.S., Neame P.B. A platelet function defect in preeclampsia. Obstet. Gynecol 1985, 65:107-109.
59. Orlikowski C.E.P., Rocke A., Murray W.B., Gouws E., Moodley J., Kenoyer D.G., et al. Thromboelastography changes in pre-eclampsia and eclampsia. Br J Anaesth 1996, 77:157-161.
60. Kobayashi T., Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antithrombin III complex and D-dimers. Gynecol Obstet Invest 1987, 24:170-178.
61. De Boer K., Ten Cate J.W., Sturk A., Borm J.J.J., Treffers P.E. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989, 160:95-100.
62. Reinthaller A., Mursch-Edlmaye G., Tatra G. Thrombin-antithrombin III complex levels in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynecol 1990, 97:506-510.
63. Dreyfus M., Hedelin G., Kutnahorsky R., Lehmann M., Viville B., Langer B., et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstet Gynecol 2001, 97:29-34.
64. Weenink G.H., Treffers P.E., Vijn P., Smorenberg-Schroorl M.E., Ten Cate J.W. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984, 148:1092-1097.
65. Weiner K.P., Kwaan H.C., Xu C., Paul M., Burmeister L., Hauck W. Antithrombin III activity in women with hypertension during pregnancy. Obstet Gynecol 1985, 65:301-306.
66. Friedman K.D., Borok Z., Owen J. Heparin cofactor activity and antithrombin III antigen levels in preeclampsia. Thromb Res 1986, 43:409-416.
67. Paternoster D.M., Stella A., Simioni P., Girolami A., Snijders D. Activated protein C resistance in normal and pre-eclamptic pregnancies. Gynecol Obstet Invest 2002, 54:145-149.
68. Bombeli T., Raddatz-Mueller P., Fehr J. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women. Am J Obstet Gynecol 2001, 184:382-389.
69. Hayashi M., Hamada Y., Ohkura T. Thrombin-antithrombin complex and a -plasmin inhibitor- 2 plasmin complex levels after cesarean section in normal pregnancies and pre-eclampsia. International J Gynecol Obstet 2003, 82:213-216.
70. Erez O., Romero R., Kim S.S., Kim J.S., Kim Y.M., Wildman D.E., et al. Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med 2008, 21:345-355.
71. Lockwood C.J., Toti P., Arcuri F., Norwitz E., Funai E.F., Huang S.T., et al. Thrombin regulates soluble fms-like Tyrosine Kinase-1 (sFlt-1) expression in first trimester decidua. Am J Path 2007, 170:1398-1405.
72. Tusar K., Giri, Douglas M., Tollefsen Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 2006, 107:2753-2758.
73. Matta P., Lockwood C.J., Schatz F., Krikun G., Rahman M., Buchwalder L., et al. Thrombin regulates monocyte chemoattractant protein-1 expression in human first-trimester and term decidual cells. Am J Obstet Gynecol 2007, 196:268-271.
74. O'Sullivan C.J., Allen N.M., O'Loughlin A.J., Friel A.M., Morrison J.J. Thrombin and PAR1-activating peptide: Effects on human uterine contractility in vitro. Am J Obstet Gynecol 2004, 190:1098-1105.
75. Chaiworapongsa T., Yoshimatsu J., Espinoza J., Kim Y.M., Berman S., Edwin S., et al. Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia. J Matern Fetal Neonatal Med 2002, 11:362-367.
76. VanWijk M.J., Boer K., Berckmans R.J., Meijers J.C., van der Post J.A., Sturk A., et al. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002, 88:415-420.
77. Shu F., Sugimura M., Kanayama N., Kobayashi H., Kobayashi T., Terao T. Immunohistochemical study of annexin V expression in placentae of preeclampsia. Gynecol Obstet Invest 2000, 49:17-23.
78. Graeff H., Von Hugo R., Schrock R. Recent aspects of hemostasis, hematology and hemorheology in preeclampsia-eclampsia. Eur J Obstet Gynec Reprod Biol 1984, 17:91-102.
79. Grisaru D., Zwang E., Peyser M.R., Lessing J.B., Eldor A. The procoagulant activity of red blood cells from patients with severe preeclampsia. Am J Obstet Gynecol 1997, 177:1513-1516.
80. Kaibara M., Mitsuhashi Y., Watanabe T., Tamiaki F., Nishihira M., Sadatsuki M., et al. Effects of red cells on the coagulation of blood in normal and preeclamptic pregnancies. Am J Obstet Gynecol 1999, 180:402-405.
81. Thorburn J., Drummond M.M., Whigham K.A., Lowe G.D.O., Forbes C.D., Prentice C.R.M., et al. Blood viscosity and haemostatic factors in late pregnancy, pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 1982, 89:117-122.
82. Cunningham F.G., Lowe T., Guss S., Mason R. Erythrocyte morphology in women with severe preeclampsia and eclampsia. Preliminary observations with scanning electron microscopy. Am J Obstet Gynecol 1985, 153:358-363.
83. Von Dadelszen P., Wilkins T., Redman C.W.G. Maternal peripheral blood leucocytes in normal and preeclamptic pregnancies. Br J Obstet Gynaecol 1999, 106:576-581.
84. Kobayashi H., Sadakata H., Suzuki K., She M.Y., Shibata S., Terao T. Thrombomodulin release from umbilical endothelial cells initiated by preeclampsia plasma-induced neutrophil activation. Obstet Gynecol 1998, 92:425-430.
85. Bellart J., Gilabert R., Angles A., Piera V., Miralles R.M., Monasterio, et al. Tissue factor levels and high ratio fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 1999, 106:594-597.
86. Many A., Schreiber L., Rosner S., Lessing J.B., Eldor A., Kupferminc M.J. Pathologic Features of the Placenta in Women With Severe Pregnancy Complications and Thrombophilia. Obstet Gynecol 2001, 98:1041-1044.
87. Aharon A., Lanir N., Drugan A., Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost 2005, 3:2355-2357.
88. Glueck C.J., Kupferminc M.J., Fontaine R.N., Wang P., Weksler B.B., Eldor A. Genetic hypofibrinolysis in complicated pregnancies. Obstet Gynecol 2001, 97:44-48.
89. De Maat M.P., Jansen M.W., Hille E.T., Vos H.L., Bloemenkamp K.W., Buitendijk S., et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004, 2:1588-1593.
90. Alacacioĝlu I., Ozcan M.A., Alacacioälu A., Polat M., Yüksel F., Demirkan F., et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 2004, 114:155-159.
91. Antovic J.P., Rafik Hamad R., Antovic A., Blombäck M., Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation ?. Thromb Haemost 2002, 88:644-647.
92. Baptista-Gonzalez H.A., Rosenfeld-Mann F., Saavedra-Trejo M.R., Castro-Lopezj L., Penuela-Olaya M.A. Changes in the thrombophilic status in patients with pre-eclampsia. Ginecol Obstet Mex 1999, 67:176-182.
93. Mjahed K., Hammamouchi B., Hammoudi D., Harti A., Miguil M., Barrou L. Analyse critique des troubles de 1'hémostase au cours de l'éclampsie. J Gynecol Obstet Biol Reprod 1998, 27:607-610.
94. Borok Z., Weitz J., Owen J., Auerbach M., Nossel H.L. Fibrinogen proteolysis and platelet alpha-granule release in preeclampsia/eclampsia. Blood 1984, 63:525-531.
95. Gaffney P.J., Creighton L.J., Callus M., Thorpe R. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). II. Evaluation in a variety of clinical conditions. Br J Haematol 1988, 68:91-96.
96. Trofatter K.F., Howell M.L., Greenberg C.S., Hage M.L. Use of the Fibrin D-Dimer in screening for coagulation abnormalities in preeclampsia. Obstet Gynecol 1989, 73:435-439.
97. Ho C.H., Yang Z.L. The predictive value of the hemostasis parameters in the development of preeclampsia. Thromb Haemost 1992, 67:214-218.
98. Verduzco Rodriguez L., Puebla G.E., Manffrini M.F., Ariza L.B. D-Dimer in different stages of pregnancy toxemia. A pilot study. Gynecol Obstet Mex 1998, 66:77-80.
99. Nakashima A., Kobayashi T., Terao T. Fibrinolysis during normal pregnancy and severe preeclampsia: relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest 1996, 42:95-101.
100. Schjetlein R., Haugen G., Wisloff F. Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation. Acta Obstet Gynecol Scand 1997, 76:541-546.
101. Sibai B.M., Kustermann L., Velasco J. Current understanding of severe preeclampsia, pregnancy-associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, hemolysis, elevated liver enzymes, and low platelets syndrome, and postpartum acute renal failure: different clinical syndromes or just different names. Curr Opin Nephrol Hypertens 1994, 3:436-445.
102. Pourrat O., Beaufils F. Insuffisance rénale aiguë du post-partum. Insuffisance rénale aiguë en réanimation 2003, Elsevier, Paris, p. 295-309.
103. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584.
104. Lattuada A., Rossi E., Calzarossa C., Candolfi R., Mannucci P.M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003, 88:1029-1034.
105. Hulstein J.J., van Runnard Heimel P.J., Franx A., Lenting P.J., Bruinse H.W., Silence K., et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 2006, 4:2569-2575.
106. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004, 103:4003-4009.
107. De Moerloose P. Le syndrome des anticorps antiphospholipides. Manuel d'hémostase 1995, 507-528. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
108. Preston F.E., Rosendaal F.R., Walker I.D., Briet E., Berntorp E., Conard J., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348:913-916.
109. Kupferminc M.J., Eldor A., Steinman N., Many A., Bar-Am A., Jaffa A., et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999, 340:9-13.
110. Van Pampus M.G., Dekker G.A., Wolf H.W., Huijgens P.C., Koopman M.M.W., Von Blomberg M.E., et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999, 180:1146-1150.
111. Peltier J.Y., De Mazancourt P., Beaufils F., Benmebarek Y., Doleans M., Richard L., et al. Incidence of metabolic and hemostatic variables in 72 women with pregnancy-induced hypertension. Thromb Haemost 1999, 82:A1681.
112. Dizon-Townson D.S., Nelson L.M., Easton K., Ward K. The factor V Leiden may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996, 175:902-905.
113. Wiener-Megnani Z., Ben-Shlomo I., Goldberg Y., Shalev E. Resistance to activated protein C and the Leiden mutation: High prevalence in patients with abruptio placentae. Am J Obstet Gynecol 1998, 179:1565-1567.
114. Dekker G.A., de Vries J.I.P., Doelitzsch P.M., Huijgens P.C., Von Blomberg B.M.E., Jackobs C. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995, 173:1042-1048.
115. Von Tempelhoff G.F., Heilmann L., Spanuth E., Kunzmann E., Hommel G. Incidence of the Factor V Leidenmutation, Coagulation Inhibitor Deficiency, and Elevated Antiphospholipid-antibodies in Patients with Preeclampsia or HELLP Syndrome. Thrombosis Research 2000, 100:363-365.
116. De Vries J.I.P., Dekker G.A., Huijgens P.C., Jackobs C., Blomberg B.M.E., Van Geijn H.P. H yperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol 1997, 104:1248-1254.
117. Krauss T., Augustin H.G., Osmers R., Meden H., Unterhalt M., Kuhn W. Activated Protein C resistance and factor V leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998, 92:457-460.
118. Khong T.Y., Hague W.M. The placenta in maternal hyperhomocysteinaemia. Br J Obstet Gynaecol 1999, 106:273-278.
119. Arias F., Romero R., Joist H., Kraus F.T. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998, 7:277-286.
120. De Groot C.J., Bloemenkamp K.W., Duvetot E.J., Helmerhorst F.M., Bertina R.M., Van De Meer F., et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999, 181:975-980.
121. Kahn S.R., Platt R.W., McNamara H., Rozen R., Chen M.F., Genest J., et al. Inherited Thrombophilia and preeclampsia within a multicenter cohort: the montreal preeclampsia study. Am J Obstet Gynecol 2009, 200:151-159.
122. Dalmáz C.A., Santos K.G., Botton M.R., Tedoldi C.L., Roisenberg I. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. Blood Cells Mol Dis 2006, 37:107-110.
123. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
124. Stone S., Hunt B.J., Khamashta M.A., Bewley S.J., Nelson-Piercy C. Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 2005, 3:243-245.
125. Pauzner R., Dulizky M., Carp H., Mayan H., Kenett R., Farfel Z., et al. Hepatic infarctions during pregnancy are associated with the antiphospholipid syndrome and in addition with complete or incomplete HELLP syndrome. J Thromb Haemost 2003, 1:1758-1763.
126. Queyrel V., Ducloy-Bouthors A.S., Michon-Pasturel U., Hachulla E., Dubucquoi S., Caron C., et al. Antiphospholipid antibodies in HELLP syndrome: clinical and biological study in 68 women. Rev Med Interne 2003, 24:158-164.
127. Mohan Rao V., Hoang A.D., Rapaport S.I. Mechanism and Effects of the Binding of Lupus Anticoagulant IgG and Prothrombin to Surface Phospholipid. Blood 1996, 88:4173-4182.
128. Galli M., Barbui T. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome. Blood 1999, 93:2149-2157.
129. Jacob J.H., Wu X.X., Andrée H.A.M., Ross J.B.A., Rusinova E., Gascon-Lema M.G., et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A " Lupus procoagulant" phenomenon. Blood 1998, 92:1652-1660.
130. Chamley L.W., Duncalf A.M., Mitchell M.D., Johnson P.M. Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998, 352:1037-1038.
131. Empson M., Lassere M., Craig J., Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005, 18:CD002859.
132. Pritchard J.A., Cunningham F.G., Pritchard S.A., Mason R.A. How often does maternal preeclampsiaeclampsia incite thrombocytopenia in the fetus?. Obstet Gynecol 1987, 69:292-295.
133. Cederholm-Williams S.A., Spencer J.A.D., Wilkinson A.R. Plasma levels of selected haemostatic factors in newborn babies. Thromb Res 1981, 23:555-558.
134. Zanardo V., Savio V., Sabrina G., Franzoi M., Zerbinati P., Fadin M., et al. The effect of pre-eclampsia on the levels of coagulation and fibrinolysis factors in umbilical cord blood of newborns. Blood Coagul Fibrinolysis 2005, 16:177-181.
135. Tanjung M.T., Siddik H.D., Hariman H., Koh S.C. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 2005, 11:467-473.
136. Ophir E., Dourleshter G., Hirsh Y., Fait V., German L., Bornstein J. Newborns of pre-eclamptic women: a biochemical difference present in utero. Acta Obstet Gynecol Scand 2006, 85:1172-1178.
137. Andresen M.S., Iversen N., Abildgaard U. Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin. Thrombosis Research 2003, 108:323-328.
138. Whitten C.W., Greilich P.E. Thromboelastography Past, Present, and Future. Anesthesiology 2000, 92:1223-1225.
139. Rai R., Cohen H., Dave M., Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with antiphospholipid antibodies. BMJ 1997, 314:253-257.
140. Riyazi N., Leeda M., De Vries J.L., Huijgens P.C., Van Geijn H.P., Dekker G.A. Low -molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998, 80:49-54.
141. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
142. Carp H., Dolitzky M., Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003, 1:433-438.
143. Paidas M., Ku D.H., Triche E., Lockwood C., Arkel Y. Does heparin therapy improve pregnancy outcome in patients with thrombophilias?. J Thromb Haemost 2004, 2:1194-1195.
144. Grandone E., Margaglione M. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. J Thromb Haemost 2004, 2:1187-1188.
145. Conard J. Antithrombotic prophylaxis in women with thrombophilia and pregnancy complications. J Thromb Haemost 2004, 2:1190-1192.
146. Sergio F., Maria Clara D., Gabriella F., Giorgia S., De Carolis S., Giancarlo P., et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy 2006, 25:115-127.
147. Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. J Thromb Haemost 2004, 2:1183-1184.
148. Gris J.C., Mercier E., Quere I., Lavigne-Lissalde G., Cochery-Nouvellon E., Hoffet M., et al. Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004, 103:3695-3699.
149. Howie P.W., Prentice C.R., Forbes C.D. Failure of heparin therapy to affect the clinical course of severe preeclampsia. Br J Obstet Gynaecol 1975, 82:711-717.
150. Forestier F., Sole Y., Aiach M., Alhenc-Gelas M., Daffos F. Absence of transplacental passage of fragmin (Kabi) in the second and third trimesters of pregnancy. Thromb Haemost 1992, 67:180-181.
151. Deruelle P., Denervaud M., Hachulla E., Ducloy-Bouthors A.S., Valat A.S., Puech F., et al. Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006, 127:73-78.
152. Leperc J., Conard J., Borel-Derlon A., Darmon J.Y., Boudignat O., Francoual C., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001, 108:1134-1140.
153. Malinow M.R., Duell P.B., Hess D.L., Anderson P.H., Kruger W.D., Phillipson B.E., et al. Reduction of plasma homocyst(e)ine levels with folic acid in patients with coronary heart disease. N Engl J Med 1998, 338:1009-1015.
154. Martin J.N., Files J.C., Blake P.G., Norman P.H., Martin R.W., Hess L.W., et al. Plasma exchange for preeclampsia. Am J Obstet Gynecol 1990, 162:126-137.
155. Martin J.N., Files J.C., Blake P.G., Perry K.G., Morrison J.C., Norman P.H. Postpartum plasma exchange for atypical preeclampsia-eclampsia as HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1995, 172:1107-1125.
156. Watson W.J., Katz V.L., Bowes W.A. Plasmapheresis during pregnancy. Obstet Gynecol 1990, 76:451-457.
157. Del Fante C., Perotti C., Viarengo G., Gallini G.S., Tinelli C., Salvaneschi L. Daily plasma-exchange for lifethreatening class I HELLP syndrome with prevalent pulmonary involvement. Transfus Apher Sci 2006, 34:7-9.
158. Wang Y., Walli A.K., Schulze A., Blessing F., Fraunberger P., Thaler C., et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus Apher Sci 2006, 35:103-110.
159. Sibai B.M., Ramanathan M.K., Usta I., Salama M., Mercer B.M., Friedman S.A. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes and low platelets. Am J Obstet Gynecol 1993, 169:1000-1006.
160. Shinyama H., Akira T., Uchida T., Hirahara K., Watanabe M., Kagitani Y. Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in preeclampsia. J Cardiovascular Pharmacol 1996, 27:702-711.
161. Harada N., Okajima K., Kushimoto S., Isobe H., Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999, 93:157-164.
162. Terao T. Coagulopathy in preeclampsia. Biomedical Progress 2000, 13:10-14.
163. Terao T., Kobayashi T., Imai N., Oda H., Karasawa T. Pathological state of the coagulatory and fibrinolytic system in preeclampsia and the possibility of its treatment with AT III concentrate. Asia-Oceania. J Obstet Gynaecol 1989, 15:25-32.
164. Paternoster D.M., De Fusco D., Tambuscio B. Treatment with antithrombin III AT III concentrate in preeclampsia. Intern J Gynecol Obstet 2000, 71:175-176.
165. Paternoster D.M., Fantinato S., Manganelli F., Milani M., Nicolini U., Girolami A. Efficacy of AT in preeclampsia: a case-control prospective trial. Thromb Haemost 2004, 91:283-289.
166. Di Micco B., Colonna G., Di Micco P., Di Micco G., Russo B.M., Macalello M.A., et al. Anti-thrombin action of low-dose acetylsalicylic acid. Eur J Pharmacol 2003, 460:59-62.
167. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999, 82:718-721.
168. Eschwege V., Toti F., Robert A., Freyssinet J.M. Les antithrombotiques: perspectives. Manuel d'hémostase 1995, 757-772. Elsevier, Paris. J. Sampol, D. Arnoux, B. Boutière (Eds.).
169. Dekker G.A., Van Geijn H.P. Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cells dysfunction in preeclampsia; therapeutic perspectives. J Perinat Med 1996, 24:I19-39.
170. Vigil-De Gracia P. Addition of platelet transfusions to corticosteroids does not increase the recovery of severe HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 2006, 128:194-198.
171. Magann E.F., Bass D., Chauhan S.P. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994, 171:1148-1153.
172. O'Brien J.M., Milligan D.A., Barton J.R. Impact of high-dose corticosteroid therapy for patients with HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2000, 183:921-924.
173. Martin J.N., Thigpen B.D., Rose C.H., Cushman J., Moore A., May W.L. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003, 189:830-834.
174. Martin JN, MD, Rose CH, Briery CM. Understanding and managing HELLP syndrome: The integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006;195:914-34.
175. Isler C.M., Barrilleaux P.S., Magann E.F., Bass J.D., Martin J.N. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. Am J Obstet Gynecol 2001, 184:1332-1339.
176. Tompkins M.J., Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: The benefit of corticosteroids. Am J Obstet Gynecol 1999, 181:304-309.
177. Dreyfus M., Tissier I., Ndocko M.A., Denoual I., Baldauf J.J., Ritter J. Corticosteroid therapy for conservative management in marginally-viable pregnancy complicated by HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1999, 85:233-234.
178. Mecacci F., Carignani L., Cioni R., Parretti E., Mignosa M., Piccioli A., et al. Time Course of Recovery and Complications of HELLP. Syndrome with Two Different Treatments: Heparin or Dexamethasone. Thromb Res 2001, 102:99-105.
179. Yalcin O.T., Sener T., Hassa H., Ozalp S., Okur A. Effects of postpartum corticosteroids in patients with HELLP syndrome. Intern J Gynecol Obstet 1998, 61:141-148.
180. Isler C.M., Magann E.F., Rinehart B.K., Terrone D.A., Bass J.D., Martin J.N. Dexamethasone compared with betamethasone for glucocorticoid treatment of postpartum HELLP syndrome. Intern J Gynecol Obstet 2003, 80:291-297.
181. Vigil-De Gracia P., Garcia-Caceres E. Dexamethasone in the post-partum treatment of HELLP syndrome. Intern J Gynecol Obstet 1997, 59:217-221.
182. Tsatsaris V., Carbonne B., Dupré La Tour M., Cabrol D., Milliez J. Is conservative treatment of HELLP syndrome safe?. Eur J Obstet Gynecol Reprod Biol 1998, 80:139-141.
183. Fonseca J.E., Mendez F., Catano C., Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: A double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol 2005, 193:1591-1598.
184. Sher G., Statland B.E. Abruptio placentae with coagulopathy: a rational basis for management. Clin Obstet Gynecol 1985, 28:15-23.
185. Ahonen J., Jokela R., Korttila K. An open non-randomized study of recombinant activated factor VII in major post-partum haemorrhage. Acta Anaesthesiol Scand 2007, 51:929-936.
186. Maki M., Terao T., Ikenuo T., Takeruma T., Sekiba K., Shirakawa K., et al. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 1987, 23:230-240.
187. Bragenberg R., Bodensohn M., Burger U. Antithrombin-III substitution in preterm infants-effects on intracranial hemorrhage and coagulation parameters. Biol Neonate 1997, 72:76-83.
188. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999, 353:1258-1265.
189. Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale. Recommandations pour la pratique clinique. SFAR 2005.
190. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008, 198:233-237.